Brought to you by 
Momenta, Sandoz develop and market complex drugs; expanded in separate deal
21 Apr 2021
Executive Summary
Momenta (sugar sequencing and engineering) will combine its complex sugars technologies with the expertise of Novartis' generic unit Sandoz to jointly develop and market a generic equivalent of injectable enoxaparin--generic of Lovenox-- and potential improved forms of it. The drug is a low-molecular weight heparin for preventing and treating deep vein thrombosis and for treating acute coronary syndromes.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
-
Biotechnology
- Drug Discovery Tools
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Momenta, Sandoz develop and market complex drugs; expanded in separate deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice